Public hearings as a transparency measure: The Valproate case
Research output: Contribution to conference › Conference abstract for conference › Research
Standard
Public hearings as a transparency measure: The Valproate case. / Møllebæk, Mathias.
2017.Research output: Contribution to conference › Conference abstract for conference › Research
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - ABST
T1 - Public hearings as a transparency measure: The Valproate case
AU - Møllebæk, Mathias
PY - 2017/10/2
Y1 - 2017/10/2
N2 - In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens’ accounts positioned vis-à-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group?
AB - In line with increasing calls of transparency initiatives across European institutions, the European Medicines Agency (EMA) will on September 26th 2017 host its first public hearing on the regulatory of a drug, namely Valproate. According to the EMA website, the public hearing is intended to “increase transparency by opening up the scientific evaluation process” and “[give citizens] a voice in the evaluation of medicines.” This conference paper will present the preliminary results from a rhetorical analysis of the public hearing as a transparency measure. What kind transparency does a public hearing provide? How are citizens’ accounts positioned vis-à-vis expert testimonies? Does the public hearing achieve sufficient “hybridity” of its heterogeneous stakeholder group?
M3 - Conference abstract for conference
ER -
ID: 184327103